Segui
monica crugnola
monica crugnola
Affiliazione sconosciuta
Email verificata su ao.pr.it
Titolo
Citata da
Citata da
Anno
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
C Cesana, C Klersy, L Barbarano, AM Nosari, M Crugnola, E Pungolino, ...
Journal of Clinical Oncology 20 (6), 1625-1634, 2002
3442002
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
N Giuliani, F Morandi, S Tagliaferri, M Lazzaretti, S Bonomini, M Crugnola, ...
Blood, The Journal of the American Society of Hematology 110 (1), 334-338, 2007
3042007
Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ...
Cancer 126 (6), 1243-1252, 2020
1222020
Survival of elderly patients with acute myeloid leukemia
A Pulsoni, L Pagano, R Latagliata, M Casini, R Cerri, M Crugnola, ...
haematologica 89 (3), 296-302, 2004
1082004
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival
N Giuliani, S Bonomini, P Romagnani, M Lazzaretti, F Morandi, S Colla, ...
Haematologica 91 (11), 1489-1497, 2006
1022006
Differences among young adults, adults and elderly chronic myeloid leukemia patients
F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ...
Annals of Oncology 26 (1), 185-192, 2015
1012015
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
L Arcaini, M Paulli, S Burcheri, A Rossi, M Spina, F Passamonti, M Lucioni, ...
British journal of haematology 136 (2), 301-304, 2007
972007
Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients
S Colla, F Morandi, M Lazzaretti, R Rizzato, P Lunghi, S Bonomini, ...
Leukemia 19 (12), 2166-2176, 2005
962005
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
M Bocchia, A Sicuranza, E Abruzzese, A Iurlo, S Sirianni, A Gozzini, ...
Frontiers in Oncology 8, 194, 2018
942018
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
F Palandri, R Latagliata, N Polverelli, A Tieghi, M Crugnola, B Martino, ...
Leukemia 29 (6), 1344-1349, 2015
912015
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ...
Blood advances 3 (24), 4280-4290, 2019
812019
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia
R Latagliata, M Breccia, C Fava, F Stagno, M Tiribelli, L Luciano, ...
Hematological oncology 31 (2), 103-109, 2013
812013
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease
K Todoerti, G Lisignoli, P Storti, L Agnelli, F Novara, C Manferdini, ...
Experimental hematology 38 (2), 141-153, 2010
772010
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
F Palandri, GA Palumbo, M Bonifacio, M Tiribelli, G Benevolo, B Martino, ...
Oncotarget 8 (45), 79073, 2017
752017
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
C Fava, G Rege-Cambrin, I Dogliotti, M Cerrano, P Berchialla, M Dragani, ...
haematologica 104 (8), 1589, 2019
732019
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
S Monfardini, SML Aversa, V Zoli, L Salvagno, A Bianco, R Bordonaro, ...
Annals of oncology 16 (8), 1352-1358, 2005
642005
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia …
F Palandri, F Castagnetti, I Iacobucci, G Martinelli, M Amabile, G Gugliotta, ...
haematologica 95 (8), 1415, 2010
622010
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
S Soverini, C De Benedittis, KM Polakova, J Linhartova, F Castagnetti, ...
Oncotarget 7 (16), 21982, 2016
612016
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients
M Breccia, F Efficace, S Sica, E Abruzzese, M Cedrone, D Turri, M Gobbi, ...
Leukemia research 39 (10), 1055-1059, 2015
602015
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG
A Olivieri, G Santini, C Patti, T Chisesi, C De Souza, A Rubagotti, ...
Annals of oncology 16 (12), 1941-1948, 2005
552005
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20